Want to see ALLO full AI Analyst Report?

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

1,784 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALLO Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Allogene

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALLO Stock 12 Month Forecast

Average Price Target

$8.59

▲(259.21% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $8.59 with a high forecast of $14.00 and a low forecast of $3.85. The average price target represents a 259.21% change from the last price of $2.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.996923076923077,3.913846153846154,4.830769230769231,5.747692307692308,6.664615384615384,7.581538461538462,8.49846153846154,9.415384615384616,10.332307692307692,11.249230769230769,12.166153846153847,13.083076923076923,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.5803846153846157,3.080769230769231,3.581153846153846,4.081538461538462,4.581923076923077,5.082307692307692,5.582692307692308,6.0830769230769235,6.583461538461539,7.083846153846155,7.5842307692307696,8.084615384615386,{"y":8.585,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.2161538461538464,2.352307692307692,2.4884615384615385,2.624615384615385,2.760769230769231,2.896923076923077,3.0330769230769232,3.1692307692307695,3.3053846153846154,3.4415384615384617,3.577692307692308,3.713846153846154,{"y":3.85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$8.59

Lowest Price Target$3.85

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Biren Amin

Piper Sandler

$10

Buy

318.41%

Upside

Reiterated

05/29/26

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Immunovant (IMVT)

Sami Corwin

William Blair

―

Buy

―

Reiterated

05/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Pharvaris (NASDAQ: PHVS) and Allogene Therapeutics (NASDAQ: ALLO)

John Newman

Canaccord Genuity

$14

Buy

485.77%

Upside

Reiterated

05/14/26

Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)

Matthew Biegler

Oppenheimer

Buy

192.89%

Upside

Reiterated

05/14/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

05/13/26

Analysts' Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN)

Luca Issi

RBC Capital

Buy

276.57%

Upside

Reiterated

05/13/26

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Biogen (NASDAQ: BIIB) and COMPASS Pathways (NASDAQ: CMPS)

Robert Burns

H.C. Wainwright

$12→$11

Buy

360.25%

Upside

Reiterated

04/16/26

Allogene Therapeutics price target raised to $12 from $8 at H.C. WainwrightAllogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright

Brian Cheng

J.P. Morgan

―

Hold

―

Upgraded

04/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Roger Song

Jefferies

$6→$10

Buy

318.41%

Upside

Reiterated

04/15/26

Allogene Therapeutics price target raised to $10 from $6 at JefferiesAllogene Therapeutics price target raised to $10 from $6 at Jefferies

William Pickering

Bernstein

$1.6→$3.85

Hold

61.09%

Upside

Reiterated

04/14/26

Bernstein Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)

Reni Benjamin

Citizens JMP

$5→$8

Buy

234.73%

Upside

Reiterated

04/14/26

Allogene Therapeutics price target raised to $8 from $5 at CitizensAllogene Therapeutics price target raised to $8 from $5 at Citizens

Jack Allen

Robert W. Baird

$7→$9

Buy

276.57%

Upside

Reiterated

04/14/26

Allogene Therapeutics price target raised to $9 from $7 at BairdAllogene Therapeutics price target raised to $9 from $7 at Baird

Samantha Semenkow

Citi

Buy

67.36%

Upside

Assigned

04/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Asthika Goonewardene

Truist Financial

$10

Buy

318.41%

Upside

Reiterated

03/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Michael Yee

UBS

Buy

234.73%

Upside

Initiated

01/06/26

Allogene Therapeutics initiated with a Buy at UBSAllogene Therapeutics initiated with a Buy at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Biren Amin

Piper Sandler

$10

Buy

318.41%

Upside

Reiterated

05/29/26

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Immunovant (IMVT)

Sami Corwin

William Blair

―

Buy

―

Reiterated

05/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Pharvaris (NASDAQ: PHVS) and Allogene Therapeutics (NASDAQ: ALLO)

John Newman

Canaccord Genuity

$14

Buy

485.77%

Upside

Reiterated

05/14/26

Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)

Matthew Biegler

Oppenheimer

Buy

192.89%

Upside

Reiterated

05/14/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

05/13/26

Analysts' Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN)

Luca Issi

RBC Capital

Buy

276.57%

Upside

Reiterated

05/13/26

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Biogen (NASDAQ: BIIB) and COMPASS Pathways (NASDAQ: CMPS)

Robert Burns

H.C. Wainwright

$12→$11

Buy

360.25%

Upside

Reiterated

04/16/26

Allogene Therapeutics price target raised to $12 from $8 at H.C. WainwrightAllogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright

Brian Cheng

J.P. Morgan

―

Hold

―

Upgraded

04/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Roger Song

Jefferies

$6→$10

Buy

318.41%

Upside

Reiterated

04/15/26

Allogene Therapeutics price target raised to $10 from $6 at JefferiesAllogene Therapeutics price target raised to $10 from $6 at Jefferies

William Pickering

Bernstein

$1.6→$3.85

Hold

61.09%

Upside

Reiterated

04/14/26

Bernstein Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)

Reni Benjamin

Citizens JMP

$5→$8

Buy

234.73%

Upside

Reiterated

04/14/26

Allogene Therapeutics price target raised to $8 from $5 at CitizensAllogene Therapeutics price target raised to $8 from $5 at Citizens

Jack Allen

Robert W. Baird

$7→$9

Buy

276.57%

Upside

Reiterated

04/14/26

Allogene Therapeutics price target raised to $9 from $7 at BairdAllogene Therapeutics price target raised to $9 from $7 at Baird

Samantha Semenkow

Citi

Buy

67.36%

Upside

Assigned

04/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Asthika Goonewardene

Truist Financial

$10

Buy

318.41%

Upside

Reiterated

03/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Michael Yee

UBS

Buy

234.73%

Upside

Initiated

01/06/26

Allogene Therapeutics initiated with a Buy at UBSAllogene Therapeutics initiated with a Buy at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Allogene Therapeutics

3 Months

Sami CorwinWilliam Blair

Success Rate

10/21 ratings generated profit

Average Return

-3.06%

Copying Sami Corwin's trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of -3.06% per trade.

1 Year

Sami CorwinWilliam Blair

Success Rate

8/21 ratings generated profit

Average Return

+0.21%

Copying Sami Corwin's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of +0.21% per trade.

2 Years

Sami CorwinWilliam Blair

Success Rate

9/21 ratings generated profit

Average Return

+0.18%

Copying Sami Corwin's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +0.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALLO Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALLO has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ALLO average Analyst price target in the past 3 months is 8.59.

Each month's total comprises the sum of three months' worth of ratings.

ALLO Financial Forecast

ALLO Earnings Forecast

Next quarter’s earnings estimate for ALLO is -$0.17 with a range of -$0.23 to -$0.13. The previous quarter’s EPS was -$0.18. ALLO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.

ALLO Sales Forecast

Next quarter’s sales forecast for ALLO is $2.00K with a range of $0.00 to $20.00K. The previous quarter’s sales results were $0.00. ALLO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.

ALLO Stock Forecast FAQ

What is ALLO’s average 12-month price target, according to analysts?

Based on analyst ratings, Allogene Therapeutics’s 12-month average price target is 8.59.

What is ALLO’s upside potential, based on the analysts’ average price target?

Allogene Therapeutics has 259.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALLO a Buy, Sell or Hold?

Allogene Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Allogene Therapeutics’s price target?

The average price target for Allogene Therapeutics is 8.59. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $3.85. The average price target represents 259.21% Increase from the current price of $2.39.

What do analysts say about Allogene Therapeutics?

Allogene Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of ALLO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

ALLO Analyst Ratings

ALLO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Allogene Therapeutics

ALLO Analyst Recommendation Trends

ALLO Financial Forecast

ALLO Earnings Forecast

ALLO Sales Forecast

ALLO Stock Forecast FAQ

Detailed List of Analyst Forecasts